Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) was downgraded by equities researchers at Vetr from a “strong-buy” rating to a “buy” rating in a report issued on Monday. They presently have a $161.19 price target on the specialty pharmaceutical company’s stock. Vetr‘s target price indicates a potential upside of 11.88% from the company’s current price.

JAZZ has been the topic of several other research reports. Cantor Fitzgerald restated a “buy” rating and set a $187.00 price objective on shares of Jazz Pharmaceuticals plc – in a report on Thursday, January 12th. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals plc – from a “hold” rating to a “sell” rating in a report on Thursday, March 2nd. Guggenheim restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals plc – in a report on Thursday, February 9th. Leerink Swann restated a “buy” rating on shares of Jazz Pharmaceuticals plc – in a report on Wednesday, January 18th. Finally, Deutsche Bank AG set a $148.00 price objective on shares of Jazz Pharmaceuticals plc – and gave the stock a “buy” rating in a report on Wednesday, February 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $178.32.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 6.91% during mid-day trading on Monday, hitting $144.08. 1,753,586 shares of the stock were exchanged. The stock’s 50-day moving average is $131.85 and its 200 day moving average is $119.55. Jazz Pharmaceuticals plc – has a 52 week low of $95.80 and a 52 week high of $160.00. The company has a market capitalization of $8.61 billion, a PE ratio of 22.48 and a beta of 1.22.

Your IP Address:

In related news, SVP Michael Patrick Miller sold 200 shares of the stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $137.89, for a total transaction of $27,578.00. Following the completion of the transaction, the senior vice president now owns 22,762 shares in the company, valued at $3,138,652.18. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Paul Treacy sold 884 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $131.97, for a total transaction of $116,661.48. Following the transaction, the senior vice president now owns 18,108 shares of the company’s stock, valued at approximately $2,389,712.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,484 shares of company stock valued at $709,335. Company insiders own 3.90% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Strs Ohio raised its position in Jazz Pharmaceuticals plc – by 21.0% in the third quarter. Strs Ohio now owns 215,160 shares of the specialty pharmaceutical company’s stock valued at $26,137,000 after buying an additional 37,392 shares during the last quarter. BlackRock Japan Co. Ltd raised its position in Jazz Pharmaceuticals plc – by 1.2% in the third quarter. BlackRock Japan Co. Ltd now owns 77,214 shares of the specialty pharmaceutical company’s stock valued at $9,380,000 after buying an additional 909 shares during the last quarter. Tamarack Advisers LP bought a new position in Jazz Pharmaceuticals plc – during the third quarter valued at $12,082,000. DIAM Co. Ltd. raised its position in Jazz Pharmaceuticals plc – by 6.6% in the third quarter. DIAM Co. Ltd. now owns 70,452 shares of the specialty pharmaceutical company’s stock valued at $8,665,000 after buying an additional 4,387 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp raised its position in Jazz Pharmaceuticals plc – by 0.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 124,531 shares of the specialty pharmaceutical company’s stock valued at $15,128,000 after buying an additional 609 shares during the last quarter. Institutional investors own 88.56% of the company’s stock.

About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.